"I've had a lot of calls and emails asking me about the impact of currently ongoing clinical trials by Geron and Advanced Cell Technology.
We at International Stem Cell Corporation are delighted to see companies entering clinical trials with pluripotent stem cells. The success of all companies in our field aids ISCO as well and each new disease or injury that scientists demonstrate to be treatable with stem cells represents another potential market for our pluripotent stem cells in the future."
Kenneth Aldrich - CEO of International Stem Cell Corporation